Drug company GlaxoSmithKline pleaded guilty to violations involving 10 drugs and was ordered to pay a fine of $3bn.
Stephen Whitehead, chief executive of Association of the British Pharmaceutical Industry, told the Today programme he believes GlaxoSmithKline have since led "new ethical practices" and their culture has "dramatically changed".
He defends the industry as having "the highest standards" of clinical trial disclosure and marketing practices, as well as ensuring "absolute total transparency".
"We are truly trying to rebuild our social contract... and trying to address these trust issues," he told John Humphrys.
Get in touch with Today via
or text us on 84844.